Medical Writer · PhD Biological Sciences

Science that speaks. Writing that works.

A decade at the bench. Now translating complex clinical evidence into strategic, compelling narratives that empower healthcare providers to make informed decisions and improve patient outcomes.

View My WorkGet in Touch

Domain Expertise

Diabetes and Metabolic Disorders
Cardiovascular and Pulmonary Disorders
Oncology
Immunology
Vinny Negi

About Me

A scientist who writes. A writer who understands the science.

With a foundation in science and a passion for clarity, I develop evidence-driven content designed for healthcare professionals. My work transforms complex data into actionable insights that empower confident clinical decisions and advance patient care.

PhD, Biological Sciences
MSc, Biotechnology
BSc, Biochemistry
Read full bio

Portfolio

Selected Work

View all samples
Poster
HFpEFObesityGLP-1R agonist

Semaglutide improves life quality of HFpEF patients with obesity - a phase III study (STEP-HFpEF)

Heart failure with preserved ejection fraction (HFpEF) comprises about 50% of heart failure cases, affecting at least 64 million people worldwide. Obesity is a major driver for HFpEF; obese patients have severe symptoms such as increased inflammation, reduced exercise capacity, and exertion, degrading life quality. Current medications are not effective in treating HFpEF in obese patients. There is a need for a new drug to improve their quality of life. Earlier studies have demonstrated that weight loss improves HFpEF symptoms. We aim to determine the effect of the weight loss drug- semaglutide - a GLP-1R agonist in treating HFpEF in obese patients.

Abstract
Heart failureHFpEFobesity

A phase III study – Semaglutide improves symptoms for heart failure patients with preserved ejection and obesity

Heart failure with preserved ejection fraction (HFpEF) is one of the leading causes of death, with increasing prevalence due to the pandemic of metabolic disorders. About 80% of HFpEF patients are obese, along with other metabolic diseases, and there is no effective treatment available.

Plain Language Summary
Heart failureHFpEFGLP-1R activator

Semaglutide improves symptoms of heart failure

Heart failure is the leading cause of death worldwide. It is classified into 3 subtypes based on the heart’s pumping capacity, called left ventricular ejection fraction (LVEF). LVEF is the percentage of blood that is pumped by the heart's left ventricle to the rest of the body.

Online Article
Type 1 diabetesIslet transplantationstem cells

Transplanting insulin‑making cells to treat Type 1 diabetes is challenging − but stem cells offer a potential improvement

Diabetes develops when the body fails to manage its blood glucose levels. One form of diabetes causes the body to not produce insulin at all. Called Type 1 diabetes, or T1D, this autoimmune disease happens when the body’s defense system mistakes its own insulin-producing cells as foreign and kills them. On average, T1D can lead patients to lose an average of 32 years of healthy life.

Open Article
Online Article
GLP-1R agonistsemaglutideMASH

Semaglutide, a GLP-1R agonist, is also effective for MASH patients

Semaglutide, manufactured by Novo Nordisk under the brand names Ozempic, Wegovy, and Rybelsus, is FDA-approved for type 2 diabetes and obesity patients. Additionally, it has been tested for other diseases, such as heart and renal diseases. In a recent publication in the NEJM journal, Novo Nordisk released its interim data on the phase 3 trial of semaglutide on MASH (Metabolic Dysfunction Associated Steatohepatitis) patients. MASH is a progressive liver disease with no treatment and poor survival.

Open Article